Poseida Therapeutics' P/S ratio remains modest despite the r...
Poseida Therapeutics' P/S ratio remains modest despite the recent stock price surge. With inferior revenue forecasts and expected revenue decline, it's unlikely for a significant increase in share price in the near future.
![](https://pubimg-10000538.picsh.myqcloud.com/20220509000003089aed3635dbd.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment